The effect of letrozole on treatment of endometriosis-related infertility

Evaluation of the effect of letrozole addition to GnRH-antagonist protocol on IVF/ICSI cycle outcome in women with endometriosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150310021420N4

Enrollment

144

Registered

2018-07-13

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis-related infertility. Female infertility of other origin

Interventions

Intervention 1: Intervention group: Adding letrozole at a dose of 2.5 mg per day from the third day of the cycle to the antagonist treatment cycle for 5 days. Intervention 2: Control group: Antagonist

Eligibility

Sex/Gender

Female

Age

18 Years to 42 Years

Inclusion criteria

Inclusion criteria: consent to participation aged between 18 to 42 years BMI ranged between 18.5 to 24.9 endometriosis-induced infertility and ICSI-IVF candidate Endometriosis diagnosed by pathology reports

Exclusion criteria

Exclusion criteria: Sever Male Factor Evidence of reduced ovarian reserve (FSH levels above 10, AMH levels lower than 1, AFC reduction) Endocrine disorders (diabetes - Thyroid diseases - Hyperprolactinemia - Hypothalamic amenorrhea and ...) Known case of medical and immunologic diseases (lupus, rheumatoid arthritis, antiphospholipid syndrome, cardiovascular, liver and kidney disease) Congenital anomalies of the uterus and endometrial cavity problems (bicorn or Unicorn uterus, Asherman syndrome, myoma, polyps, etc.) Candidate for donation (egg donation and surrogacy) Recurrent IVF failures (more than three consecutive failures)

Design outcomes

Primary

Measure	Time frame
Endometrial Line Thickness (EL). Timepoint: Triggering day. Method of measurement: Trans vaginal sonography (TVS).;M II oocytes. Timepoint: after oocyte retrieval. Method of measurement: Questionnaire.;Embryo Quality. Timepoint: after ICSI. Method of measurement: Report sheet of Embryology ward.;Chemical Pregnancy. Timepoint: 2 weeks after ET. Method of measurement: BHCG Test.;Clinical pregnancy. Timepoint: Presence of pregnancy sac in ultrasound 5 weeks after ET. Method of measurement: Trans vaginal sonography (TVS).	—

Measure

Time frame

Endometrial Line Thickness (EL). Timepoint: Triggering day. Method of measurement: Trans vaginal sonography (TVS).;M II oocytes. Timepoint: after oocyte retrieval. Method of measurement: Questionnaire.;Embryo Quality. Timepoint: after ICSI. Method of measurement: Report sheet of Embryology ward.;Chemical Pregnancy. Timepoint: 2 weeks after ET. Method of measurement: BHCG Test.;Clinical pregnancy. Timepoint: Presence of pregnancy sac in ultrasound 5 weeks after ET. Method of measurement: Trans vaginal sonography (TVS).

—

Secondary

Measure	Time frame
Ongoing pregnancy. Timepoint: Ongoing pregnancy until 12 weeks of gestation. Method of measurement: sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Farid-Mojtahedi

Tehran University of Medical Sciences

m_fmojtahedi@tums.ac.ir+98 21 7788 3283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026